Emphasis on Indication [Dulaglutide (Trulicity), Exenatide (Bydureon, Byetta), Liraglutide (Victoza, Saxenda), Semaglutide (Ozempic, Wegovy, Rybelsus), Tirzepatide (Mounjaro, Zepbound)]; Application (Type 2 Diabetes, Weight Loss); Distribution Channel (Hospitals, Retail Pharmacies, Online Pharmacies); and Region/Country
The GLP-1 Analogues Market was valued at approximately USD 37 Billion in 2023 and is expected to grow at a substantial CAGR of around 28% during the forecast period (2024-2032) owing to the rising prevalence of type 2 diabetes and obesity.
GLP-1 analogues are synthetic products based on peptides that exert actions that are similar to those of the natural hormone, GLP-1. They are well employed to treat type 2 diabetes and obesity due to effectively stimulating insulin response to food intake, preventing the release of glucagon, slowing gastric emptying, and causing feelings of satiety. New generation GLP-1 analogues like liraglutide, semaglutide, and dulaglutide have shown cardiovascular pluses and proven useful in weight control interventions. Currently, they exist as injectable products and are gradually being released in oral forms to enhance compliance and convenience.
To expand the market of GLP-1 Analogues, the main strategies that continue to emerge are formulation innovation and R&D for long-acting GLP-1 analogues, enhanced oral delivery systems, and fixed-dose combination therapy using GLP-1 analogs with other products such as insulin. Moreover, cooperation agreements, license and sale agreements, and opening to promising markets in new economies are improving access. Also, there is a shift in patient focus along with direct-to-consumer promotion of treatment programs and strict patient compliance through digital health products.
For instance, on July 11, 2024, Pfizer Inc. (NYSE: PFE) announced that based on results from the ongoing pharmacokinetic study (NCT06153758), the company has selected its preferred once-daily modified release formulation for danuglipron, an oral glucagon-like peptide-1 (GLP-1) receptor agonist. Pfizer plans to conduct dose optimization studies in the second half of 2024 evaluating multiple doses of the preferred modified release formulation to inform the registration enabling studies.
This section discusses the key market trends influencing the various segments of the GLP-1 Analogues market as identified by our research experts.
The Liraglutide (Victoza, Saxenda) held a significant share of the market in 2023. Liraglutide is an area’s key driver of growth because it is a miscellaneous GLP-1 that is effective in the treatment of both type 2 diabetes and obesity with cardiovascular effects. The versatility of the product, which goes under the brand name Victoza for diabetes and Saxenda for obesity, means a wider market base. Moreover, companies concentrate on approaches to enlarging indications, enhancing marketing initiatives, and ensuring greater compliance through delivery systems. For instance, on June 24, 2024, Teva Pharmaceuticals, Inc., a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), announced the launch of an authorized generic of Victoza®1 (liraglutide injection 1.8mg), in the United States.
North America has the highest number of type 2 diabetes and obesity cases and has a highly developed healthcare system with greater penetration towards innovative therapies propelling GLP-1 analogues growth. Adding to this, the development of the market includes appropriate attitudes to reimbursement and awareness raising among patients. The companies spend significantly on research and development, introduce new products to the market, and sign contracts with healthcare institutions to increase the client base. Visibility is the reason regulatory approvals for drug and product promotions in the US and Canada are encouraged.
For instance, on December 2, 2024, the American Diabetes Association (ADA) released a guidance statement on the use of compounded GLP-1 RA (glucagon-like peptide-1 receptor agonist) and dual GIP/GLP-1 RA (glucose-dependent insulinotropic polypeptide and GLP-1 RA) medication classes. The statement recommends against using non-Food & Drug Administration (FDA)-approved compounded GLP-1 and dual GIP/GLP-1 RA products due to uncertainty about their content, safety, quality, and effectiveness.
The GLP-1 Analogues market is competitive, with several global and international players. The key players are adopting different growth strategies to enhance their market presence, such as partnerships, agreements, collaborations, new product launches, geographical expansions, and mergers and acquisitions. Some of the major players operating in the market are Novo Nordisk A/S, Lilly, Sanofi, AstraZeneca, Pfizer Inc., Boehringer Ingelheim International GmbH, Amgen Inc., ZEALAND PHARMA, Merck & Co., Inc., Hanmi Pharm.Co.,Ltd.
On June 12, 2023, Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced that new findings for efinopegdutide (MK-6024), an investigational GLP-1/glucagon receptor co-agonist, have been accepted for oral presentation at the European Association for the Study of the Liver (EASL) Annual Congress from June 21-24.
On May 13, 2022, The U.S. Food and Drug Administration (FDA) approved Mounjaro™ (tirzepatide) injection, Eli Lilly and Company's (NYSE: LLY) new once-weekly GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptor agonist indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes. Mounjaro has not been studied in patients with a history of pancreatitis and is not indicated for use in patients with type 1 diabetes mellitus.
Report Attribute | Details |
Base year | 2023 |
Forecast period | 2024-2032 |
Growth momentum | Accelerate at a CAGR of 28% |
Market size 2023 | USD 37 Billion |
Regional analysis | North America, Europe, Asia-Pacific, Rest of the World |
Major contributing region | Asia-Pacific is expected to grow at the highest CAGR during the forecasted period. |
Key countries covered | U.S., Canada, Germany, France, UK, Spain, Italy, China, Japan, and India |
Companies profiled | Novo Nordisk A/S, Lilly, Sanofi, AstraZeneca, Pfizer Inc., Boehringer Ingelheim International GmbH, Amgen Inc., ZEALAND PHARMA, Merck & Co., Inc., Hanmi Pharm.Co.,Ltd. |
Report Scope | Market Trends, Drivers, and Restraints; Revenue Estimation and Forecast; Segmentation Analysis; Demand and Supply Side Analysis; Competitive Landscape; Company Profiling |
Segments Covered | By Indication, By Application, By Distribution Channel, By Region/Country |
The study includes market sizing and forecasting analysis validated by authenticated key industry experts.
The report presents a quick review of overall industry performance at one glance.
The report covers an in-depth analysis of prominent industry peers with a primary focus on key business financials, product portfolios, expansion strategies, and recent developments.
Detailed examination of drivers, restraints, key trends, and opportunities prevailing in the industry.
The study comprehensively covers the market across different segments.
Deep dive regional level analysis of the industry.
The global GLP-1 Analogues market can be customized further as per the requirement or any other market segment. Besides this, UMI understands that you may have your own business needs, hence feel free to connect with us to get a report that completely suits your requirements.
1. Market Introduction
2. Research Methodology or Assumption
3. Executive Summary
4. Market Dynamics
5. Pricing Analysis
6. Global Glp-1 Analogues Market Revenue (USD Bn), 2022-2032F
7. Market Insights By Indication
8. Market Insights By Application
9. Market Insights By Distribution Channel
10. Market Insights By Region
11. Value Chain Analysis
12. Competitive Landscape
13. Company Profiled
14. Acronyms & Assumption
15. Annexure
Analyzing the historical market, estimating the current market, and forecasting the future market of the global GLP-1 Analogues market were the three major steps undertaken to create and analyze the adoption of GLP-1 Analogues in major regions globally. Exhaustive secondary research was conducted to collect the historical market numbers and estimate the current market size. Secondly, to validate these insights, numerous findings and assumptions were taken into consideration. Moreover, exhaustive primary interviews were also conducted, with industry experts across the value chain of the global GLP-1 Analogues market. Post assumption and validation of market numbers through primary interviews, we employed a top-down/bottom-up approach to forecasting the complete market size. Thereafter, market breakdown and data triangulation methods were adopted to estimate and analyze the market size of segments and sub-segments of the industry. Detailed methodology is explained below:
Step 1: In-Depth Study of Secondary Sources:
A detailed secondary study was conducted to obtain the historical market size of the GLP-1 Analogues market through company internal sources such as annual reports & financial statements, performance presentations, press releases, etc., and external sources including journals, news & articles, government publications, competitor publications, sector reports, third-party database, and other credible publications.
Step 2: Market Segmentation:
After obtaining the historical market size of the GLP-1 Analogues market, we conducted a detailed secondary analysis to gather historical market insights and share for different segments & sub-segments for major regions. Major segments are included in the report as indication, application, Distribution Channel, and regions. Further country-level analyses were conducted to evaluate the overall adoption of testing models in that region.
Step 3: Factor Analysis:
After acquiring the historical market size of different segments and sub-segments, we conducted a detailed factor analysis to estimate the current market size of the GLP-1 Analogues market. Further, we conducted factor analysis using dependent and independent variables such as indication, application, Distribution Channel, and regions of the GLP-1 Analogues market. A thorough analysis was conducted for demand and supply-side scenarios considering top partnerships, mergers and acquisitions, business expansion, and product launches in the GLP-1 Analogues market sector across the globe.
Current Market Sizing: Based on actionable insights from the above 3 steps, we arrived at the current market size, key players in the global GLP-1 Analogues market, and market shares of the segments. All the required percentage shares split and market breakdowns were determined using the above-mentioned secondary approach and were verified through primary interviews.
Estimation & Forecasting: For market estimation and forecast, weights were assigned to different factors including drivers & trends, restraints, and opportunities available for the stakeholders. After analyzing these factors, relevant forecasting techniques i.e., the top-down/bottom-up approach were applied to arrive at the market forecast for 2032 for different segments and sub-segments across the major markets globally. The research methodology adopted to estimate the market size encompasses:
The industry’s market size, in terms of revenue (USD) and the adoption rate of the GLP-1 Analogues market across the major markets domestically
All percentage shares, splits, and breakdowns of market segments and sub-segments
Key players in the global GLP-1 Analogues market in terms of products offered. Also, the growth strategies adopted by these players to compete in the fast-growing market
Primary Research: In-depth interviews were conducted with the Key Opinion Leaders (KOLs) including Top Level Executives (CXO/VPs, Sales Head, Marketing Head, Operational Head, Regional Head, Country Head, etc.) across major regions. Primary research findings were then summarized, and statistical analysis was performed to prove the stated hypothesis. Inputs from primary research were consolidated with secondary findings, hence turning information into actionable insights.
The data triangulation technique was employed to complete the overall market estimation and to arrive at precise statistical numbers for each segment and sub-segment of the global GLP-1 Analogues market. Data was split into several segments and sub-segments after studying various parameters and trends in the indication, application, distribution channel, and regions of the global GLP-1 Analogues market.
The current & future market trends of the global GLP-1 Analogues market were pinpointed in the study. Investors can gain strategic insights to base their discretion for investments on the qualitative and quantitative analysis performed in the study. Current and future market trends determined the overall attractiveness of the market at a regional level, providing a platform for the industrial participant to exploit the untapped market to benefit from a first-mover advantage. Other quantitative goals of the studies include:
Analyze the current and forecast market size of the GLP-1 Analogues market in terms of value (USD). Also, analyze the current and forecast market size of different segments and sub-segments.
Segments in the study include areas of indication, application, distribution channel, and regions.
Define and analyze the regulatory framework for the GLP-1 Analogues
Analyze the value chain involved with the presence of various intermediaries, along with analyzing customer and competitor behaviors of the industry.
Analyze the current and forecast market size of the GLP-1 Analogues market for the major region.
Major countries of regions studied in the report include Asia Pacific, Europe, North America, and the Rest of the World
Company profiles of the GLP-1 Analogues market and the growth strategies adopted by the market players to sustain the fast-growing market.
Deep dive regional level analysis of the industry
Q1: What is the GLP-1 Analogues market's current size and growth potential?
The GLP-1 Analogues market was valued at USD 37 Billion in 2023 and is expected to grow at a CAGR of 28% during the forecast period (2024-2032).
Q2: What are the driving factors for the growth of the GLP-1 Analogues market?
The rising prevalence of type 2 diabetes and obesity, innovations such as oral formulations and long-acting drugs, increased patient awareness, and regulatory approvals drive the GLP-1 Analogues market.
Q3: Which segment has the largest share of the GLP-1 Analogues market by indication?
Liraglutide (Victoza, Saxenda) has the largest share of the GLP-1 Analogues market by indication
Q4: What are the major trends in the GLP-1 Analogues market?
The rise of oral formulations, and combination therapy development is the major trend in the GLP-1 Analogues market.
Q5: Which region will dominate the GLP-1 Analogues market?
North America dominated the market in 2023.
Customers who bought this item also bought
Antibiotic Resistance Market: Current Analysis and Forecast (2024-2032)
Emphasis on Disease Type (Urinary Tract Infections, Intra-Abdominal Infections, Blood Stream Infections, Clostridium Difficile Infections, And Others); Pathogen Type (Acinetobacter baumannii, Pseudomonas aeruginosa, Staphylococcus aureus, Streptococcus pneumoniae, and Others); Drug Class (Oxazolidinones, Lipoglycopeptides, Tetracyclines, and Others); and Region/Country
October 8, 2024
